Skin cancer is the most common cancer worldwide and can be differentiated in sub categories of melanoma and non-melanoma. When diagnosed at its earlier stage, skin cancer has an almost 99% survival rate of 5 or more years. A majority of skin cancers will be treated conventionally with surgery and/or radiotherapy. A small percentage of patients progress to locally advanced or metastatic disease, most commonly as a result of patient negligence, comorbidities, or immunosuppression.
The development of tumors involves many different genetic alterations commonly involved in cell growth and proliferation. The advancement of gene expression analysis has allowed us to identify and classify these alterations. Prognostic gene signatures have provided insight into molecular subgroups, oncogenic drivers and novel therapeutic strategies for skin cancer. Expression signatures are important in guiding treatment selection and predicting outcome in tumor patients. Genomic studies have provided insights into molecular subgroups and oncogenic drivers of skin cancers that may lead to novel therapeutic strategies. Identifying potential biomarkers of skin cancers may provide critical information for early detection of relapse or treatment.
Existing treatments for a number of different skin cancers are not effective against tumour metastases. Research has begun shifting its efforts to targeted therapies, immune checkpoint inhibitors or adaptive T-cell therapies. Identifying genetic and epigenetic alterations has led to the development of research into targeted therapies in skin cancer.
For this Research Topic, we welcome submissions of Original Research and Reviews highlighting the advancements of prognostic gene signatures in the treatment of skin cancers.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Skin cancer is the most common cancer worldwide and can be differentiated in sub categories of melanoma and non-melanoma. When diagnosed at its earlier stage, skin cancer has an almost 99% survival rate of 5 or more years. A majority of skin cancers will be treated conventionally with surgery and/or radiotherapy. A small percentage of patients progress to locally advanced or metastatic disease, most commonly as a result of patient negligence, comorbidities, or immunosuppression.
The development of tumors involves many different genetic alterations commonly involved in cell growth and proliferation. The advancement of gene expression analysis has allowed us to identify and classify these alterations. Prognostic gene signatures have provided insight into molecular subgroups, oncogenic drivers and novel therapeutic strategies for skin cancer. Expression signatures are important in guiding treatment selection and predicting outcome in tumor patients. Genomic studies have provided insights into molecular subgroups and oncogenic drivers of skin cancers that may lead to novel therapeutic strategies. Identifying potential biomarkers of skin cancers may provide critical information for early detection of relapse or treatment.
Existing treatments for a number of different skin cancers are not effective against tumour metastases. Research has begun shifting its efforts to targeted therapies, immune checkpoint inhibitors or adaptive T-cell therapies. Identifying genetic and epigenetic alterations has led to the development of research into targeted therapies in skin cancer.
For this Research Topic, we welcome submissions of Original Research and Reviews highlighting the advancements of prognostic gene signatures in the treatment of skin cancers.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
